The Adrenal Contribution to Androgen Production in Girls During Puberty
NCT01062568
Completed
In girls with elevated androgens the precise source of androgen excess throughout puberty and early adolescence has not been carefully examined. The investigators propose to examine whether the adrenal gland produces the majority of androgens during puberty by studying the differences in androgen responses to adrenocorticotropin hormone (ACTH) administration in normal weight (NW) and obese (OB) girls ages 7-18. The investigators' analyses will compare steroid changes before and 60 min after ACTH... Read More
Gender:
FEMALE
Ages:
Between 7 years and 18 years
Trial Updated:
08/08/2019
Locations: University of california, san diego, La Jolla, California
Conditions: Development
Register for Updates
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT01363817
Completed
The purpose of this study is to identify a safe and tolerable dose of BMS-906024, either alone or in combination with Dexamethasone in subjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma who no longer respond to or have relapsed from standard therapies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2019
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +5 locations
Conditions: Lymphoblastic Leukemia, Acute T-cell, Precursor T-Cell Lymphoblastic Lymphoma
Register for Updates
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
NCT02648490
Completed
This study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of humanized anti-EGFR monoclonal antibody, HLX07, in patients with epithelial cancer who have failed standard therapy and deemed unamenable by conventional therapy. This study will also evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor effect of HLX07 and explore the potential prognostic and predictive biomarkers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2019
Locations: Henlix, Inc., Fremont, California +1 locations
Conditions: Solid Tumour
Register for Updates
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
NCT00004228
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/24/2019
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +175 locations
Conditions: Lymphoma
Register for Updates
Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction
NCT02525718
Completed
Subjects are being asked to participate in this study because they will be undergoing unilateral (one) or bilateral (two) mastectomy surgery with immediate reconstruction involving insertion of a tissue expander.
Gender:
FEMALE
Ages:
Between 18 years and 79 years
Trial Updated:
07/24/2019
Locations: Northwestern University, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
NCT02535806
Terminated
This is a phase II study designed to investigate the combination of bortezomib with the mitoxantrone reinduction regimen used in the ALL R3 trial. The study will enroll patients with high risk ALL relapse including early bone marrow relapse and second or greater relapse of any kind. Patients with relapsed LL will also be eligible. Bone marrow evaluation will be performed after blood counts recover to assess the rate of CR (\<5% bone marrow blasts) and MRD status in children following this regime... Read More
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
07/23/2019
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Register for Updates
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
NCT01722305
Completed
This phase I trial studies the side effects and best dose of pomalidomide when given together with dexamethasone in treating patients with primary central nervous system lymphoma that has come back (relapsed) or does not respond to treatment (refractory) or intraocular lymphoma that is newly diagnosed, relapsed or refractory. Pomalidomide may stimulate the immune system to kill cancer cells. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer ce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2019
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +6 locations
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma, Intraocular Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Recurrent Adult Diffuse Large Cell Lymphoma, Retinal Lymphoma
Register for Updates
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
NCT02880228
Completed
This phase II trial studies how well pembrolizumab, lenalidomide, and dexamethasone work in treating patients with newly diagnosed multiple myeloma that are eligible for stem cell transplant. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2019
Locations: Mayo Clinic in Florida, Jacksonville, Florida +1 locations
Conditions: Plasma Cell Myeloma
Register for Updates
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
NCT02159365
Completed
To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2019
Locations: Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona +28 locations
Conditions: Multiple Myeloma
Register for Updates
Study of the Effectiveness of Ozurdex for the Control of Uveitis
NCT02049476
Completed
The main purpose of this study is to evaluate whether or not the dexamethasone pellet (Ozurdex®, Allergan, Irvine, CA) can replace oral corticosteroid (e.g. prednisone) in the treatment of active sight-threatening, noninfectious intermediate and/or posterior uveitis in which immunosuppressive drug therapy is indicated. Uveitis is an inflammation inside the eye. Uveitis can decrease patients' vision if it is not treated. The dexamethasone pellet is an implant filled with a corticosteroid medici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2019
Locations: The Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Uveitis, Intermediate, Uveitis, Posterior
Register for Updates
Corticosteroids for Children With Febrile Urinary Tract Infections
NCT01391793
Completed
In this study the investigators will determine whether corticosteroids given at the time of urinary tract infection help prevent permanent damage to the kidneys.
Gender:
ALL
Ages:
Between 2 months and 6 years
Trial Updated:
06/24/2019
Locations: Children's National Medical Center, Washington, District of Columbia +5 locations
Conditions: Acute Urinary Tract Infection, Urinary Tract Infection
Register for Updates
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
NCT02046070
Completed
This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior systemic treatment for multiple myeloma (MM) and who are ineligible for high-dose therapy (HDT)-stem cell transplantation (SCT) due to age (ie, ≥ 65 years) or comorbid disease(s) or with Relapsed and/or Refractory Multiple Myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2019
Locations: Not set, Hazard, Kentucky +23 locations
Conditions: Multiple Myeloma
Register for Updates